Ultragenyx Pharmaceutical Inc.
RARE
$26.84
$0.542.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 136.00M | 207.28M | 159.93M | 166.50M | 139.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 136.00M | 207.28M | 159.93M | 166.50M | 139.00M |
| Cost of Revenue | 173.00M | 232.63M | 244.20M | 187.74M | 174.00M |
| Gross Profit | -37.00M | -25.35M | -84.27M | -21.24M | -35.00M |
| SG&A Expenses | 86.00M | 87.94M | 86.62M | 86.65M | 87.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 275.00M | 320.56M | 330.82M | 274.38M | 282.00M |
| Operating Income | -139.00M | -113.28M | -170.89M | -107.89M | -143.00M |
| Income Before Tax | -184.00M | -127.69M | -179.54M | -114.00M | -150.00M |
| Income Tax Expenses | 1.00M | 870.00K | 873.00K | 947.00K | 1.00M |
| Earnings from Continuing Operations | -185.00M | -128.56M | -180.41M | -114.95M | -151.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -185.00M | -128.56M | -180.41M | -114.95M | -151.00M |
| EBIT | -139.00M | -113.28M | -170.89M | -107.89M | -143.00M |
| EBITDA | -131.00M | -104.50M | -162.28M | -99.27M | -134.00M |
| EPS Basic | -1.84 | -1.29 | -1.81 | -1.17 | -1.57 |
| Normalized Basic EPS | -0.96 | -0.80 | -1.13 | -0.72 | -0.97 |
| EPS Diluted | -1.84 | -1.29 | -1.81 | -1.17 | -1.57 |
| Normalized Diluted EPS | -0.96 | -0.80 | -1.13 | -0.72 | -0.97 |
| Average Basic Shares Outstanding | 100.60M | 99.90M | 99.77M | 98.46M | 96.30M |
| Average Diluted Shares Outstanding | 100.60M | 99.90M | 99.77M | 98.46M | 96.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |